메뉴 건너뛰기




Volumn 58, Issue 12, 2009, Pages 1703-

Long-term safety of Infliximab for the treatment of inflammatory bowel disease: Does blocking TNFα reduce colitis-associated colorectal carcinogenesis?

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

EID: 72549112691     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.176461     Document Type: Letter
Times cited : (16)

References (5)
  • 1
    • 63849251824 scopus 로고    scopus 로고
    • Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study
    • Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:477-478
    • (2009) Gut , vol.58 , pp. 477-478
    • Fidder, H.1    Schnitzler, F.2    Ferrante, M.3
  • 4
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies
    • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006;295:2275-2285
    • (2006) JAMA , vol.295 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.